{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:56:02Z","timestamp":1783436162354,"version":"3.54.6"},"reference-count":64,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cjcopen.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CJC Open"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.cjco.2024.01.001","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T04:33:50Z","timestamp":1705034030000},"page":"708-720","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease With Recent or Remote Events: Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"6","author":[{"given":"Ahmad","family":"Hayek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair J.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Marquis-Gravel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R.","family":"Bainey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret L.","family":"Ackman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren J.","family":"Cantor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3967-1528","authenticated-orcid":false,"given":"Ricky D.","family":"Turgeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjco.2024.01.001_bib1","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.4244\/EIJV10I9A174","article-title":"Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement","volume":"10","author":"Capodanno","year":"2015","journal-title":"EuroIntervention"},{"key":"10.1016\/j.cjco.2024.01.001_bib2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2024.01.001_bib3","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2024.01.001_bib4","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2024.01.001_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000086918","article-title":"Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting","volume":"104","author":"Rubboli","year":"2005","journal-title":"Cardiology"},{"key":"10.1016\/j.cjco.2024.01.001_bib6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective: 2021 update","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2024.01.001_bib7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Neumann","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2024.01.001_bib8","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2024.01.001_bib9","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2024.01.001_bib10","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2024.01.001_bib11","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2024.01.001_bib12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/europace\/euz259","volume":"22","author":"Potpara","year":"2020","journal-title":"Europace"},{"key":"10.1016\/j.cjco.2024.01.001_bib13","article-title":"Safety and efficacy of double antithrombotic therapy with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"9","author":"Capodanno","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjco.2024.01.001_bib14","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/CIRCULATIONAHA.118.036248","article-title":"Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy","volume":"139","author":"van Rein","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2024.01.001_bib15","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.113.004834","article-title":"Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study","volume":"129","author":"Lamberts","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2024.01.001_bib16","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.cjco.2024.01.001_bib17","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cjco.2024.01.001_bib18","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cjco.2024.01.001_bib19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cjco.2024.01.001_bib20","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2024.01.001_bib21","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1161\/CIRCULATIONAHA.117.029289","article-title":"Standardized end point definitions for coronary intervention trials: the Academic Research Consortium-2 consensus document","volume":"137","author":"Garcia-Garcia","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2024.01.001_bib22","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2024.01.001_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027498","article-title":"Management of stable coronary artery disease and atrial fibrillation with anti-thrombotic therapy: a systematic review and meta-analysis","volume":"100","author":"Malladi","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cjco.2024.01.001_bib24","doi-asserted-by":"crossref","first-page":"474","DOI":"10.7326\/M19-3763","article-title":"Dual versus triple therapy for atrial fibrillation after percutaneous coronary intervention: a systematic review and meta-analysis","volume":"172","author":"Khan","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjco.2024.01.001_bib25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cjca.2019.11.005","article-title":"Dual-antithrombotic therapy with DOACs after acute coronary syndrome or percutaneous coronary intervention in atrial fibrillation: a meta-analysis of randomized controlled trials","volume":"36","author":"Shurrab","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2024.01.001_bib26","first-page":"CD013252","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs) postpercutaneous coronary intervention: a network meta-analysis","volume":"12","author":"Al Said","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cjco.2024.01.001_bib27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/heartjnl-2019-315963","article-title":"P2Y12 inhibitors with oral anticoagulation for percutaneous coronary intervention with atrial fibrillation: a systematic review and meta-analysis","volume":"106","author":"Lupercio","year":"2020","journal-title":"Heart"},{"key":"10.1016\/j.cjco.2024.01.001_bib28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ijcard.2022.03.047","article-title":"The optimal duration of triple antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention: a network meta-analysis of randomized clinical trials","volume":"357","author":"Wang","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjco.2024.01.001_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-036138","article-title":"Safety and efficacy of dual versus triple antithrombotic therapy (DAT vs TAT) in patients with atrial fibrillation following a PCI: a systematic review and network meta-analysis","volume":"10","author":"Altoukhi","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.cjco.2024.01.001_bib30","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/1074248420930136","article-title":"Safety and efficacy of oral anticoagulants therapies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis","volume":"25","author":"Mainka","year":"2020","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.cjco.2024.01.001_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.832164","article-title":"Comparative safety and efficacy of eight antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"9","author":"Liang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cjco.2024.01.001_bib32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.carrev.2021.05.013","article-title":"Antithrombotic therapy with or without aspirin after percutaneous coronary intervention or acute coronary syndrome in patients taking oral anticoagulation: a meta-analysis and network analysis of randomized controlled trials","volume":"36","author":"Colleran","year":"2022","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.cjco.2024.01.001_bib33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40256-020-00436-8","article-title":"Meta-analysis comparing potent oral P2Y12 inhibitors versus clopidogrel in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"21","author":"Casula","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.cjco.2024.01.001_bib34","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.amjcard.2019.11.022","article-title":"Meta-analysis of antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"125","author":"Kuno","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjco.2024.01.001_bib35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/MCA.0000000000000900","article-title":"Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome undergoing percutaneous coronary intervention; insights from a meta-analysis","volume":"32","author":"Kuno","year":"2021","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.cjco.2024.01.001_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235511","article-title":"Dual anti-thrombotic treatment with direct anticoagulants improves clinical outcomes in patients with atrial fibrillation with ACS or undergoing PCI. A systematic review and meta-analysis","volume":"15","author":"De Rosa","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.cjco.2024.01.001_bib37","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s11739-020-02402-3","article-title":"Benefit of dual antithrombotic therapy with direct oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and metaanalysis of randomized clinical trials","volume":"15","author":"Zoppellaro","year":"2020","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.cjco.2024.01.001_bib38","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/pace.14081","article-title":"New oral anticoagulants for nonvalvular atrial fibrillation with stable coronary artery disease: a meta-analysis","volume":"43","author":"Cen","year":"2020","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.cjco.2024.01.001_bib39","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/FJC.0000000000000938","article-title":"Direct oral anticoagulants versus vitamin-K antagonist after PCIs in patients with AF: a meta-analysis of cardiac ischemic events","volume":"77","author":"Cordero","year":"2021","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjco.2024.01.001_bib40","article-title":"Optimisation of oral anticoagulants for patients with atrial fibrillation within 12 months after percutaneous coronary intervention: a meta-analysis and systematic review","volume":"36","author":"Wang","year":"2021","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.cjco.2024.01.001_bib41","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ccd.29192","article-title":"Antithrombotic strategies in patients needing oral anticoagulation undergoing percutaneous coronary intervention: a network meta-analysis","volume":"97","author":"Saglietto","year":"2021","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.cjco.2024.01.001_bib42","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000024188","article-title":"Double antithrombotic therapy for prevention of bleeding and ischemic events after percutaneous coronary intervention in patients with atrial fibrillation: a meta-analysis","volume":"100","author":"Qiu","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cjco.2024.01.001_bib43","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/ehjcvp\/pvz030","article-title":"Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared to triple therapy","volume":"6","author":"Galli","year":"2020","journal-title":"Eur Hear J Cardiovasc Pharmacother"},{"key":"10.1016\/j.cjco.2024.01.001_bib44","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","volume":"40","author":"Gargiulo","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2024.01.001_bib45","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.carrev.2019.08.015","article-title":"Dual versus triple antithrombotic therapy after acute coronary syndrome or percutaneous coronary intervention in patients with atrial fibrillation: an updated meta-analysis","volume":"21","author":"Goel","year":"2020","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.cjco.2024.01.001_bib46","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamacardio.2019.1880","article-title":"Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials","volume":"4","author":"Lopes","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjco.2024.01.001_bib47","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamacardio.2019.6175","article-title":"Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network meta-analysis","volume":"5","author":"Lopes","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjco.2024.01.001_bib48","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11239-020-02041-7","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary artery disease: a meta-analysis of randomized controlled trials","volume":"50","author":"Kheiri","year":"2020","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.cjco.2024.01.001_bib49","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejim.2020.06.035","article-title":"Safety and efficacy of anticoagulant monotherapy in atrial fibrillation and stable coronary artery disease: a systematic review and meta-analysis","volume":"81","author":"Ullah","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.cjco.2024.01.001_bib50","doi-asserted-by":"crossref","DOI":"10.1177\/10760296221074681","article-title":"Safety and efficacy evaluation of antithrombotic therapy with rivaroxaban and clopidogrel after PCI in Chinese patients","volume":"28","author":"Bai","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.cjco.2024.01.001_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106365","article-title":"Efficacy and safety of rivaroxaban and ticagrelor in elderly patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"104","author":"Liu","year":"2021","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.cjco.2024.01.001_bib52","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1161\/CIRCULATIONAHA.120.046534","article-title":"Risk\/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS","volume":"141","author":"Alexander","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2024.01.001_bib53","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jcin.2021.02.022","article-title":"Evaluation of dual versus triple therapy by landmark analysis in the RE-DUAL PCI trial","volume":"14","author":"Peterson","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.cjco.2024.01.001_bib54","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCULATIONAHA.118.036768","article-title":"Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation","volume":"139","author":"Matsumura-Nakano","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2024.01.001_bib55","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2024.01.001_bib56","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2024.01.001_bib57","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2024.01.001_bib58","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jacc.2020.05.031","article-title":"Post-discharge bleeding and mortality following acute coronary syndromes with or without PCI","volume":"76","author":"Marquis-Gravel","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2024.01.001_bib59","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1161\/CIRCULATIONAHA.119.044584","article-title":"Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial","volume":"141","author":"Lopes","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2024.01.001_bib60","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2024.01.001_bib61","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jcin.2018.12.005","article-title":"Validation of high-risk features for stent-related ischemic events as endorsed by the 2017 DAPT guidelines","volume":"12","author":"Ueki","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.cjco.2024.01.001_bib62","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/ejcts\/ezx334","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"53","author":"Valgimigli","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.cjco.2024.01.001_bib63","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation\u2014the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ J"},{"issue":"suppl 4","key":"10.1016\/j.cjco.2024.01.001_bib64","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/S0735-1097(02)02776-6","article-title":"Oral anticoagulants in patients with coronary artery disease","volume":"41","author":"Anand","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["CJC Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X24000210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X24000210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T07:59:47Z","timestamp":1716364787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589790X24000210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2589790X24000210"],"URL":"https:\/\/doi.org\/10.1016\/j.cjco.2024.01.001","relation":{},"ISSN":["2589-790X"],"issn-type":[{"value":"2589-790X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease With Recent or Remote Events: Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"CJC Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2024.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}